This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

ASCP Corner

Real-Life Dosing With Second-Generation Antipsychotics

Christoph U. Correll, MD

Published: December 15, 2005

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

This is the first of 2 articles addressingmethodological issues regarding real-lifedosing and switching strategies whentreating patients with second-generationantipsychotics.

When faced with nonresponse to an adequateduration of antipsychotic treatmentat maximum recommended doses, clinicianshave 4 basic options to improvesymptomatic and/or functional response:(1) wait for the occurrence of a potentiallydelayed response; (2) augment with anothermedication (of the same or a differentclass); (3) switch to another medication(of the same or a different class); or(4) increase the dose beyond the upperdose range used in U.S. Food and DrugAdministration (FDA) approval trials. Ifsufficient data were available, a fifth optioncould be to check for the presence oftherapeutic antipsychotic drug levels.’ ‹

Volume: 66

Quick Links: Psychotic Disorders , Schizophrenia and Schizoaffective Disorders

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...